Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People with an ECOG performance status score of 2 or lower (a measure of how much a person's cancer affects their daily activities — confirm with trial site)
- People who have been diagnosed with Stage IV non-small cell lung cancer (NSCLC), confirmed by a tissue biopsy
- People who have already received at least one prior treatment for Stage IV NSCLC (such as targeted therapy) and whose doctors are now considering a second or later line of standard chemotherapy; in exceptional cases, people with Stage III NSCLC who have had at least one prior treatment may be considered, subject to approval by the lead investigator
- People whose liver, kidney, and other organ functions are at levels considered adequate for treatment, based on blood tests taken within 30 days before enrolling
- People who have not received any cancer treatment for at least 2 weeks before enrolling
- People whose doctors consider them suitable for treatment with a small molecule drug (a type of oral or injectable targeted medicine — confirm with trial site)
- People, or their legally authorised representative, who are able to provide written consent and authorise the release of personal health information
- Women who could become pregnant must have a negative pregnancy test result, in line with the institution's standard practice
- People who, in their enrolling doctor's judgement, are able to understand and follow the study procedures for the full duration of the trial
Who may not be able to join:
- People with an active infection that requires treatment with systemic (whole-body) medicines within 7 days of enrolling
- People with uncontrolled HIV/AIDS or an active viral hepatitis infection (such as hepatitis B or C)
- People still experiencing significant side effects from a previous cancer treatment that could interfere with assessing the safety or effectiveness of this trial, as determined by their treating doctor
- People with an ECOG performance status score greater than 2 (meaning cancer significantly limits daily activity — confirm with trial site)
- People with clinically significant lung, heart, or autoimmune disease
- People whose doctors estimate a life expectancy of less than 12 weeks
- People who have previously had a solid organ transplant (such as a kidney or liver) or a bone marrow transplant
- People who have received antibiotics, live vaccines, or undergone surgery within 4 weeks before starting trial treatment
- People who are pregnant or currently breastfeeding
- People with a prior or current separate cancer whose condition or treatment could interfere with assessing the safety or effectiveness of this trial, as determined by their treating doctor
- People with a mental or medical condition that prevents them from giving informed consent or taking part in the trial
- People with another major health condition, as determined by their treating doctor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Frank Weinberg, MD, PhD, University of Illinois at Chicago
Phone: (312) 413-7494
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To estimate the objective response rate (ORR) as measured by investigator assessment in patients with metastatic NSCLC treated with at least 2L of chemotherapy who have had OncoChoice-informed treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.